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In view of the important oncogenic action of phospholipase A2(PLA2)w ei n v e s t i g a t e dP L A 2 transcripts in human meningiomas.
Real-time PCR was used to investigate PLA2 transcripts in 26 human meningioma tumors. Results indicated that three Ca
2+-
dependent high molecular weight PLA2 (PLA2-IVA, PLA2-IVB, PLA2-IVC), one Ca
2+-independent high molecular weight PLA2
(PLA2-VI) and ﬁve low molecular weight secreted forms of PLA2 (PLA2-IB, PLA2-IIA, PLA2-III, PLA2-V, and PLA2-XII) are
expressed with PLA2-IVA, PLA2-IVB, PLA2-VI, and PLA2-XIIA as the major expressed forms. PLA2-IIE, PLA2-IIF, PLA2-IVD,
and PLA2-XIIB are not detected. Plasma (PLA2-VIIA) and intracellular (PLA2-VIIB) platelet-activating factor acetylhydrolase
transcripts are expressed in human meningiomas. However no diﬀerence was found for PLA2 transcript amounts in relation to
the tumor grade, the subtype of meningiomas, the presence of inﬂammatory inﬁltrated cells, of an associated edema, mitosis,
brain invasion, vascularisation or necrosis. In conclusion numerous genes encoding multiples forms of PLA2 are expressed in
meningiomas where they might act on the phospholipid remodeling and on the local eicosanoid and/or cytokine networks.
Copyright © 2009 Yves Denizot et al. This is an open access article distributed under the Creative Commons Attribution License,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
1.Introduction
Meningiomas are the second most common primary
intracranial tumor. Meningiomas present clinically by caus-
ing focal or generalized seizure disorders, focal neurological
deﬁcits or neuropsychological decline [1]. A large number
of molecular and genetic pathways that are altered in
brain tumor cells have been identiﬁed. Among them, a
possible role for the eicosanoid cascade has been suggested
in meningiomas [2]. Phospholipase A2 (PLA2) is the key
enzyme involved in eicosanoid generation [3–5]. PLA2
catalyzes the hydrolysis of the sn-2 position of membrane
glycerophospholipids to liberate the eicosanoid precursor
arachidonic acid (AA) [3–5]. Four distinct families have
been documented: low molecular weight secreted forms of
PLA2 (sPLA2), Ca2+-dependent high molecular weight PLA2
(cPLA2), Ca2+-independent high molecular weight PLA2
(iPLA2); and the platelet-activating factor acetylhydrolase
(PAF-AH). The sPLA2 family is implicated in several biolog-
ical processes such as inﬂammation and host defense [3, 4].
Nine isoenzymes have been identiﬁed in human: PLA2-IB,
PLA2-IIA, PLA2-IID, PLA2-IIE PLA2-IIF, PLA2-III, PLA2-V,
PLA2-X, PLA2-XIIA, and PLA2-XIIB. In addition to their
function in digestion of dietary phospholipids, host defense
against bacteria and AA release from cellular phospholipids
for eicosanoid synthesis, two classes of receptors (M and N)
and several extracellular binding proteins have been iden-
tiﬁed indicating that sPLA2 might signal through receptor
activation [3–5]. In human the cPLA2 family consists of
four members, PLA2-IVA, PLA2-IVB, PLA2-IVC, and PLA2-
IVD; PLA2-IVA being the central regulator of stimulus-
coupledcellularAA release [3–5]. In human the iPLA2 group
consists of seven members, iPLA2 (PLA2-VIA-1) currently
being the best known member and playing major role
in phospholipids remodeling and cancer [3, 5]. Beside its
important place for eicosanoid generation, PLA2 is also the
key enzyme for the generation of the pro-inﬂammatory lipid
mediator PAF recently documented in human meningioma
[6]. PAF-AH activity which hydrolysis PAF into the inactive
PAF precursor, lyso-PAF is detected in meningioma [6].2 Mediators of Inﬂammation
However no results reported whether this enzymatic activity
originated from PLA2-VIIA and/or PLA2-VIIB, the plasma
PAF-AH and the intracellular PAF-AH forms, respectively.
Currently the contribution of PLA2 in meningiomas is
poorly documented despite the fact that PLA2 inhibition
decreased the growth of cultured meningioma cells [7].
In view of the potentially important oncogenic action of
the various PLA2 species, we investigated, at the mRNA
levels, which of them were expressed in intracranial human
meningiomas.
2.MaterialsandMethods
2.1. Patients. The procedure of the present study followed
the rules edited by the French National Ethics. Ethics
approval was obtained from the ethics committee of our
hospital (CHU Dupuytren, Limoges, France). Twenty six
patients who underwent surgery for intracranial menin-
giomas (from 1998 to 2004) were investigated. Tumors were
from the Service d’Anatomie Pathologique of the CHU
Dupuytren (France). After undergoing the routine hospital
analysis, the excess of sample was kept at −80
◦C until use
and this in accordance with the regulations in force in
France. No written or oral consent was obtained because
it is a study of samples already collected and referred to
research prior the French bioethical low (2004). Thus, ethics
committeeexplicitlyapprovedthewaiverofconsent.Normal
meninges were not available in our institution in light of
our ethic committee law. The low amounts (10–15mg)
of available tumors only permitted investigations at the
mRNA level. Tumors were classiﬁed according to the WHO
criteria [8]. There were 16 grade I meningiomas including
8 transitional (2 man, 6 women, mean age 60 years), 3
meningothelial (1 man, 2 women, mean age 60 years), and
5ﬁ b r o u s( 5w o m e n ,m e a na g e5 9y e a r s ) .H e i g h tt u m o r s
were grade II meningiomas: 7 atypical (6 men, 1 woman,
mean age 58 years) and 1 chordoid meningiomas (1 man,
54 years). Two tumors were classiﬁed as anaplastic grade
III meningiomas (2 men, mean age 54 years). Necrosis
was assessed using morphological criteria deﬁned by the
WHO classiﬁcation of meningiomas: “foci of spontaneous
or geographic necrosis”. The chronic inﬂammatory inﬁltrate
was mainly lymphoplasmocytic.
2.2. RNA Extraction. Total RNA was extracted using the
“RNeasy Lipid Tissue mini kit” (Qiagen, Courtaboeuf,
France) from 10–15mg of tumor tissue. Before RNA extrac-
tion, tumor fragments were incubated with 14mm ceramic
beads “Lysing matrix D” (Bertin Technologies, Montigny-
Le-Bretonneux, France) in 1mL QIAzol lysis reagent and
homogenized at 5500rpm during 2-fold 40sec in the auto-
mated mixer Precellys (Bertin Technologies). Then homoge-
nized samples were used for RNA puriﬁcation according to
the manufacturer’s protocol. A DNase I digestion step was
included for each extraction to avoid RNA contamination by
genomic DNA. RNA integrity was checked by capillary elec-
trophoresis on the Bioanalyzer 2100 (Agilent Technologies,
Massy, France). Only RNA with an RNA Integrity Number
(R.I.N) higher than 5.5 was used for reverse transcription.
Total RNA concentration was determined by measuring
absorbance at 260nm with a spectrophotometre NanoDrop
ND-1000 (Labtech, Paris, France).
2.3. Reverse Transcription. Total RNA was reverse tran-
scribed in single strand cDNA using random hexamers and
as described in the protocol of the “SuperScript III First-
Strand Synthesis System for RT-PCR” (Invitrogen, Cergy-
Pontoise, France). Brieﬂy, 1μg total RNA was incubated
with 200U M-MLV reverse transcriptase in the presence
of 0.5mM dNTPs, 50ng random hexamers, 5 mM MgCl2,
10mM dithiotreitol, and 40U RNase inhibitor, in a ﬁnal
volume of 20μL1 XR Tb u ﬀer. Reverse transcription was
performed as follows in a thermocycler Gold 9700 (Applied
Biosystem): denaturation during 5min at 65
◦C and chilling
1 min on ice, hybridization during 10min at 25
◦C followed
by cDNA synthesis during 50min at 50
◦C; enzyme was
inactivated by a 5min incubation at 85
◦C and chilling on ice;
ﬁnally the destruction of the RNA portion of the RNA:cDNA
hybrids was performed by 2U RNase H during 20min at
37
◦C.R eactio nsw er efr o z enat−20
◦Cuntilquantitativereal-
time PCR realisation.
2.4. Real-Time PCR Analysis. PLA2-IB, PLA2-IIA, PLA2-
IID, PLA2-IIE, PLA2-IIF, PLA2-III, PLA2-IVA, PLA2-IVB,
PLA2-IVC, PLA2-IVD, PLA2-V, PLA2-VI, PLA2-X, PLA2-
XIIA, PLA2-XIIB, PLA2-VIIA (plasma PAF-AH), PLA2-
VIIB (intracellular PAF-AH), and PLA2R transcripts were
analyzed using real-time polymerase chain reaction (PCR).
PCR was performed in duplicate by using TaqMan assay
reagents (Applied Biosystems, Foster City, CA) [9, 10]. Prod-
uct references were the following: PLA2-IB: Hs00386701-
m1; PLA2-IIA: Hs00179898-m1; PLA2-IID: Hs00173860-
m1 PLA2-IIE: Hs00173897-m1; PLA2-IIF: Hs00224482-
m1; PLA2-III: Hs00210447-m1; PLA2-IVA: Hs00233352-
m1; PLA2-IVB: Hs00979952-m1; PLA2-IVC: Hs00234345-
m1; PLA2-IVD: Hs00603557-m1; PLA2-V: Hs00173472-
m1; PLA2-VI: Hs001/85926-m1; PLA2-X: Hs00358567-m1;
PLA2-XIIA: Hs00830106-s1; PLA2-XIIB: Hs00261432-m1;
PLA2-VIIA: Hs00968593-m1; PLA2-VIIB: Hs01042135-m1;
PLA2R: Hs00234853-m1. Real-time PCR were performed
following the recommendations of the manufacturer in a
ﬁnal volume of 20μlw i t h1 0μl of 2X Universal PCR Master
Mix, 20ng of cDNA in a volume of 9μl (the amount of
cDNA is an equivalent based on the initial amount of
RNA used for the RT reaction and 1μl of a 20X TaqMan
gene expression speciﬁc probe. PCR parameters were the
following: 95
◦Cf o r1 0m i na n df o r t yc y c l e so f9 5
◦C/15sec
and 60
◦C/60sec. Ampliﬁcation products were analyzed on
an ABI Prism 7000 system (Applied Biosystems) [9, 10].
Geneexpressionlevelswerenormalizedto18SRNA(product
reference: Hs99999901-s1) according to the manufacturer’s
recommendation. Amounts of various transcripts were com-
pared to sample with the lowest level of transcripts (a patient
who was arbitrary quoted 1). The relative quantiﬁcation of
gene expression was performed using the comparative CT
method ( CT)( Figure 1(a)). Experiments were madeMediators of Inﬂammation 3
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Figure 1: Q-PCR analysis of PLA2 transcripts in human meningioma tumors. (a) Representative tracing of 18S and PLA2-IVA of tumors
from 2 diﬀerent patients (duplicate samples). (b) Detection (in duplicate) of 18S, PLA2-IVA, PLA2-IVB, PLA2-IVC, PLA2-IVD, and PLA2-VI
in a meningioma tumor.
in duplicate. Mean CT values were used in the  CT
calculation by using the “relative quantitation calculation
and analysis software for Applied Biosystems real-time PCR
systems”. NonRT controls (only with RNA) and blank RT
controls (RT without RNA) were run to make sure the
ampliﬁcations were speciﬁcs.
2.5. Data Analysis. Signiﬁcance was assessed by using the
Kruskal-Wallis test followed by a Mann-Whitney U-test.
3. Results andDiscussion
I naﬁ r s ts e to fe x p e r i m e n t sw ei n v e s t i g a t e di fm R N A s
derived from the ﬁve intracellular PLA2 genes (four cPLA2
and iPLA2) were detected in meningiomas. As shown in
Figure 1(b), mRNAs derived from four of these ﬁve cloned
PLA2 genes are detected. Mean CT values are reported in
Table 1.P L A 2-IVD transcripts were not present at detectable
levels. In contrast, PLA2-IVA, PLA2-IVB, PLA2-IVC, and
PLA2-VI were detected in 96% (25/26), 100% (26/26), 92%
(24/26),and100%(26/26)oftumors,respectively(Figure 2).
These results conﬁrm a previous study highlighting PLA2
activity in 100% of human meningiomas [6]. No diﬀerence
(P>. 05, Mann Whitney U-test) was found for PLA2
transcript amounts in relation to the tumor grade (Figure 1),
nor the subtype of meningiomas, the presence of inﬂam-
matory inﬁltrated cells, of an associated edema, mitosis,
brain invasion, vascularisation or necrosis (data not shown).
The analysis of twenty six patients indicated the following
rank of magnitude in human meningiomas: PLA2-VI =
PLA2-IVB > PLA2-IVA > PLA2-IVC (Table 1). PLA2-IVB
and PLA2-IVC had little speciﬁcity for the sn-2 fatty acid
as compared with PLA2-IVA which preferentially hydrolyses4 Mediators of Inﬂammation
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Figure 2: Cytosolic PLA2 transcripts in human meningiomas. Sixteen-grade I and eleven-grade II+III meningiomas were investigated.
Gene expression levels were normalized to 18S RNA. Amounts of transcripts were compared to sample with the lowest level of transcripts
(a patient who was arbitrary quoted 1). (◦) indicates patients with no detectable transcripts. No signiﬁcant diﬀerences were documented
between groups.
phospholipids containing AA at the sn-2 position [3–5].
PLA2-VI was originally reported to mediate phospholipid
remodeling and, thus, to act as a housekeeping protein
withoutsigniﬁcantroleincellgrowth[3,4].Howeverseveral
recent studies have demonstrated that PLA2-VI exhibited
roles in cell regulation, growth, and death. Especially, one
mechanism by which PLA2-VI mediates cell growth involves
regulation of AA release, p53, and MAPK activation [11]. Of
interest, involvements of p53 and MAPK kinase have been
recently reported in the pathology of human meningiomas
[12, 13]. A role for PLA2-VI may, thus, be suggested in
meningioma tumor growth. Together, these observations
might suggest PLA2-VI as a novel and interesting target
for drug development for meningioma therapy. However,
given the ubiquitous expression of PLA2-VI and its role in
glycerophospholipid metabolism, drug strategies targeting
PLA2-VI must exhibit selectivity to avoid undesired side
eﬀects.
In a second set of experiments we investigated if mRNAs
derived from the nine sPLA2 genes (i.e., PLA2-IB, PLA2-IIA,
PLA2-IID, PLA2-IIE, PLA2-IIF, PLA2-III, PLA2-V, PLA2-X,
PLA2-XIIA,andPLA2-XIIB)weredetectedinhumanmenin-
giomas.PLA2-IIE, PLA2-IIF, and PLA2-XIIB transcripts were
not present at detectable levels in tumors while PLA2-IID
and PLA2-X transcripts were detected in only a few number
(4/26, 15%) of them. In contrast, PLA2-IB, PLA2-IIA, PLA2-
III, PLA2-V and PLA2-XIIA were detected in 88% (23/26),
88% (23/26), 77% (20/26), 65% (17/26), and 96% (25/26) of
tumors, respectively (Figure 3). Mean CT values are reported
in Table 1. Results indicated the following rank of magnitude
for sPLA2 transcripts in meningiomas: PLA2-XIIA > PLA2-
IIA > PLA2-IB = PLA2-V = PLA2-III = PLA2-IID > PLA2-X.
No diﬀerence (P>. 05, Mann Whitney U-test) was found
for sPLA2 transcript amounts in relation to the tumor grade
(Figure 3), nor the subtype of meningiomas, the presence
of inﬂammatory inﬁltrated cells, of an associated edema,Mediators of Inﬂammation 5
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Figure 3:SecretedPLA2 transcriptsinhumanmeningiomas.SamelegendasinFigure 2.( ◦)indicatespatientswithnodetectabletranscripts.
No signiﬁcant diﬀerences were documented between groups.
mitosis, brain invasion, vascularisation or necrosis (data
not shown). PLA2-XIIA, PLA2-IIA, and PLA2-IB might be
implicated in meningioma growth. The physiologic roles
of PLA2-XIIA remain an open question. Whether PLA2-
XIIA exhibits a weak AA catalytic activity [14] ,ap o t e n t i a l
role for this enzyme is suggested in membrane fusion or
cell division [15]. PLA2-XIIA was reported to inhibit bone
morphogenetic protein (BMP) through the loss of activated
Smad1/4 complexes [16]; a result of importance since BMP
inhibits the tumorigenic potential of human glioblastomas6 Mediators of Inﬂammation
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Figure 4: PAF-AH and PLA2R transcripts in human meningiomas. Upper panel: plasma PAF-AH (PLA2-VIIA) and intracellular PAF-AH
(PLA2-VIIB) in meningioma tumors. Fifteen-grade I and nine-grade II+III meningiomas were investigated. (◦) indicates patients with no
detectable transcript. No signiﬁcant diﬀerences were documented between groups. Lower panel: PLA2R transcripts in ﬁfteen-grade I and
nine-grade II+III meningiomas.
by triggering the Smad signaling cascade [17]. PLA2-IB
expression is mainly neuronal in human brain [18]. Apart
from its lipolytic and pro-inﬂammatory activities, PLA2-
IB acts as receptor ligand to induce cell signaling and
subsequent activation of cPLA2, thus indirectly contributing
to AA production [19]. However the role of PLA2-IB as
a ligand for the PLA2R is still controversial. PLA2-IIA
elicits a mitogenic response and activates AA metabolism
in astrocytoma cells [20], is critical for neuronal death via
reactive oxygen species [21] and plays a role in cellular
senescence [22]. Finally, studies have suggested the role of
PLA2-IIA, PLA2-III, and PLA2-V as potential prognostic
markers in colorectal adenocarcinomas and prostate cancer
[23, 24]. The data reported in Figure 3 suggest that levels of
PLA2-IIA, PLA2-III, and PLA2-V transcripts greatly varied
betweenpatients(seetheLogscale).Woulditbepossiblethat
their levels were related to patient outcomes in meningioma
tumors? Clearly investigation of a larger number of patients
would be of interest to test this hypothesis.
In a third set of experiments we investigated PAF-
AH enzymes that constitute another PLA2 subfamily. As
shown in Figure 4 (upper panel), PLA2-VIIA (the plasma
PAF-AH form) and PLA2-VIIB (the intracellular PAF-AH
form) were present in 100% (23/23) and 95% (22/23)
meningiomatumors.MeanCT valuesarereportedinTable 1.
No diﬀerence (P>. 05, Mann Whitney U-test) was found for
PAF-AH transcript amounts in relation to the tumor grade
(Figure 4(a)), nor to other clinical data (data not shown).
The present results conﬁrm a previous study reporting PAF-
AH enzymatic activity in meningioma homogenates [6].
The PAF-AH family exhibits unique substrate speciﬁcity
toward PAF and oxidized phospholipids. Degradation of
these bioactive phospholipids by PAF-AH may lead to the
terminationofinﬂammatoryreaction.ItspresenceinhumanMediators of Inﬂammation 7
Table 1: CT values obtained during real-time PCR analysis.
Mean ± SEM CT (made on detectable samples) Number of samples with a CT > 40 (nondetectable samples)
18S 12.27 ± 0.18 0
PLA2-IB 35.35 ± 0.29 3
PLA2-IIA 33.69 ± 0.74 3
PLA2-IID 34.91 ± 0.81 22
PLA2-IIE nd 26
PLA2-IIF nd 26
PLA2-III 35.28 ± 0.50 6
PLA2-IVA 32.3 ± 0.27 1
PLA2-IVB 30.57 ± 0.33 0
PLA2-IVC 33.9 ± 0.35 2
PLA2-IVD nd 26
PLA2-V 35.81 ± 0.61 9
PLA2-VI 30.78 ± 0.30 0
PLA2-VIIA 33.19 ± 0.48 0
PLA2-VIIB 30.25 ± 1.21 1
PLA2-X 37.93 ± 0.26 22
PLA2-XIIA 32.86 ± 0.33 1
PLA2-XIIB nd 26
Results are reported as mean ± SEM of 26 experiments excepted for PLA2-VIIA and PLA2-VIIB were 23 samples were analysed. nd: not detectable CT.
meningioma is consistent with the presence of PAF in
meningioma tumors [6, 25].
Finally in a fourth set of experiments we focused our
attention on PLA2R transcripts in human meningioma. As
shown in Figure 4 (lower panel), PLA2R transcripts were
detected in 100% (23/23) meningioma tumors but without
signiﬁcant link with the tumor grade. The PLA2Rc a nacta sa
ligandforseveralsPLA2 thusmediatingavarietyofbiological
responses(suchascellproliferation,cellmigration,hormone
release,lipidmediatorproductionandcytokineproduction).
In turn, PLA2R can also play a negative role in sPLA2
functions by downregulating their exaggerated reactions
as PLA2R is involved in the degradation/internalization
of sPLA2 [26]. Particularly, PLA2R deﬁcient mice exhibit
resistance to endotoxic shock [27] and knockdown of the
PLA2R prevents the onset of replicative senescence and
diminishes stress-induced senescence [28]. Finally PLA2R
was found to be upregulated in dermatoﬁbrosarcoma [29].
Inconclusion,numerousgenesencodingmultiplesforms
of cPLA2,s P L A 2, and PAF-AH are expressed (at the mRNA
level) in human meningiomas where they might act on
tumor growth not only by acting on phospholipid remodel-
ing but also by altering the local eicosanoid and/or cytokine
networks. It is of evidence that immunhistochemistry would
be of importance to conﬁrm the relative expression of the
diﬀerent PLA2 forms in human meningioma tumors. The
discovery of speciﬁc receptors that bind sPLA2 strongly indi-
catethattheseenzymescanexertvariousbiologicalresponses
via binding to a receptor, in addition to their enzymatic
activity. Of interest meningioma tumors expressed PLA2R
transcripts. Further studies are clearly needed to elucidate
the contributions of sPLA2,c P L A 2,i P L A 2, and PAF-AH in
meningioma and to determine their possible relevance in the
targeting of new therapeutic interventions.
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